Aidence vs Tempus

Tempus has a disclosed valuation of $8.1B, while Aidence's valuation is not publicly available, making a direct size comparison difficult. Tempus employs 2500 people.

Tempus has raised more in total funding at $1.1B, compared to Aidence's $20M — a gap of $1B. Combined, the two companies have completed 8 known funding rounds.

Tempus leads with an Awaira Score of 84/100, while Aidence sits at 45/100. That 39-point gap reflects real differences in funding, scale, and traction — it's not a vanity metric.

Aidence was founded by Jeroen Vendrig in 2016. Tempus was founded by Eric Lefkofsky in 2015. Visit each company's profile on Awaira for a full founder biography.

Aidence: Aidence develops AI radiology software for lung cancer detection, building CE-marked and FDA-cleared deep learning algorithms that analyse CT scan images to identify and characterise pulmonary nodules requiring clinical follow-up. The Amsterdam company tools assist radiologists in national lung cancer screening programmes and in routine clinical CT reading, providing AI-generated nodule measurements, growth tracking, and malignancy risk scores that reduce reader variability and improve early detection rates.\n\nThe company raised approximately $20 million in venture funding and has deployed its Veye Chest algorithm across multiple European radiology networks and hospital systems participating in national lung cancer screening initiatives. Aidence received CE marking for its software as a medical device and has published clinical validation studies demonstrating performance that is non-inferior to specialist radiologist reads on lung nodule detection tasks.\n\nAidence competes in the AI radiology market alongside Annalise AI, Enlitic, Behold.ai, and Lunit, all of which target chest X-ray and CT reading assistance. The lung cancer screening market has expanded significantly as multiple European countries and the United States have implemented or planned national screening programmes for high-risk smokers, creating a growing workflow automation opportunity for AI lung nodule detection tools. The company was acquired by Coreline Soft, a South Korean medical AI company, as part of a broader consolidation in the AI radiology market. Tempus: Tempus is an AI-driven oncology and precision medicine company founded in 2015 that utilizes machine learning and data analysis to improve cancer treatment outcomes. The platform aggregates and analyzes vast datasets including clinical data, imaging, molecular information, and outcomes to identify personalized treatment strategies for cancer patients. Tempus's core technology uses artificial intelligence to match patient-specific tumor characteristics with optimal therapeutic options, enabling oncologists to make data-informed treatment decisions. The company operates primarily in the United States and serves hospitals, health systems, and oncology practices through its cloud-based platform. Its applications span multiple cancer types including lung, colorectal, breast, and ovarian cancers. Tempus has secured $1.3 billion in total funding and achieved a valuation of $8.1 billion, reflecting significant investor confidence in precision oncology. The company went public, transitioning from private to public markets. Tempus competes with other AI health platforms and precision medicine companies like Foundation Medicine and others focused on genomic analysis and treatment selection. The company's growth trajectory reflects expanding adoption of AI-driven oncology tools and increasing demand for personalized cancer treatment protocols. Its competitive positioning centers on its data infrastructure scale and machine learning capabilities applied to complex clinical decision-making. Tempus combines clinical, imaging, and molecular data through AI to provide real-time oncology treatment recommendations at scale across U.S. health systems.

Tempus got there first, launching in 2015 — that's 1 year of extra runway. Aidence didn't arrive until 2016. In AI, that kind of head start means more training data, deeper customer relationships, and a bigger talent moat.

Aidence has about 1-50 employees; Tempus has about 2500. A bigger team usually means more revenue or heavier VC backing, but in AI, small teams can build at massive scale.

Yes — they're direct rivals. Both Aidence and Tempus compete in AI Healthcare, targeting many of the same buyers. If you're evaluating one, you should be looking at the other.